VeracyteVCYT
Recorded

Veracyte UBS Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration35 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Doug SchenkelAnalyst

All right. Good afternoon. My name is Doug Schenkel. It is my pleasure to welcome, on behalf of UBS, Marc Stapley, Chief Executive Officer, and Rebecca Chambers, Chief Financial Officer from Veracyte. Thanks to both of you for being here.

Marc StapleyCEO

Pleasure. Thanks for having us.

Doug SchenkelAnalyst

Just to provide a roadmap, I thought we would start by talking about some of the Q3 updates and really trying to get a better handle on how we think about what is transitory and what is structural. Given, it feels like it was a while ago, but it was just a few days.

Rebecca ChambersCFO

I think three trading days maybe.

Doug SchenkelAnalyst

Yeah. But given it's relatively fresh, I thought it would be a good idea to start there. After that, then let's go product by product and just think about or talk through how you are thinking about the positioning of these products in 2027 and beyond. But let's start on Q3. The stock sold off materially over the last few days. The biggest reason was really the updated, if I were going to distill it to one thing, and I think it is largely this, it is really how you talked about the updated outlook for Decipher volume growth and by extension what that means for revenue growth. And of course, you also took margins to a level that I think was not drastically different from where the street is, but with a lower growth rate. You combine that with a much lower EBITDA margin than where you are this year.

Doug SchenkelAnalyst

I think those in combination were key reasons for the stock sell-off. I want to unpack the 2027 outlook in a second. But just starting on the quarter, you did come up a bit light. I think it was about 1,000 tests in Decipher. That matters, but in the aggregate, it was a good quarter. You still had really good volume growth across the board. The revenues were good. So you just unpack how you think about the quarter itself.

Marc StapleyCEO

Yeah. Happy to, Doug. And before I dive into answering your question, let me just remind people about our safe harbor statement. To the extent we are making forward-looking statements, which clearly we will, please make sure you reference the safe harbor on our website at www.veracyte.com. So yeah, I appreciate you pointing that out. I mean, actually, if you think about the things that happened in the quarter, there were very many positive momentum- Right activities that happened, things that we feel very good about.

Marc StapleyCEO

And you are right, we did miss Decipher by about 1,000 tests, which at this point is a couple of days of volume. Now, that was the second quarter where we have seen that 1,000 test miss. And we broke it down into really three factors, which I am happy to hit high level and then go into more details as you wish. But the first one is, as we kind of look back now, the NCCN guideline updates that we had in 2023 and 2024 clearly had a positive accelerative effect for what lasted for two years, and fueled growth of close to 20,000-21,000 tests a year incrementally through 2024 and 2025.

Marc StapleyCEO

When we look at that, we feel like we are at a more normalized post-effect of that level, more similar to where we were before those guideline updates, running at about what we have sized around 12,000-15,000 tests. That is the first factor. Again, happy to talk more about that in a moment. The second factor is one that we identified in Q2, continued in Q3, and I think it is pretty well validated at this point. There has been a change in low risk, precipitated by a low-risk guidance update, that took advanced testing out of the guidelines, back at the end of last year. Also, the number of patients that are being identified as low risk and treated has declined. That is the second. The third one is we cited some more competitive noise around the mindshare of our physician customers as they are getting addressed with new technologies like digital pathology AI, and that is taking time from our sales team who are spending more of their time discussing that than they are discussing the latest great evidence that has come out for Decipher, for example.

Marc StapleyCEO

Just some feedback we got from our sales team this quarter. When you put all those together, we thought it was prudent and appropriate to reset at that 12,000-15,000 level, and then invest, to tackle that third item, to invest in our sales team and commercial reach a little bit more, which again, I am also happy to talk about.

Rebecca ChambersCFO

In addition to that, I wholeheartedly agree with Marc about the Decipher drivers, but I do think also it is worth highlighting the good news in the quarter. We delivered 27% adjusted EBITDA. We generated over $40 million of cash. We initiated a $100 million buyback. We did an important acquisition, albeit one that is going to take a little bit of time to be accretive. We had multiple managed care wins. All of those are important because effectively, we will talk about the 2027 and beyond dynamics, but really when it comes down to it, there was a lot of good in the quarter that was overshadowed, understandably so, by Decipher. I am just trying to remind folks that, yes, we need to talk about Decipher.

Rebecca ChambersCFO

We need to understand it, unpack it, absolutely, but let us not forget about the other growth drivers and make sure that they also are, that the significant progress we made in the quarter is not forgotten about.

Doug SchenkelAnalyst

Yeah, that's helpful. That's why I wanted to start there, because it was, again, I think the dynamic that we've seen over the last few days is less about the quarter.

Doug SchenkelAnalyst

Absolutely It's clearly more about 2027.

Doug SchenkelAnalyst

That being said, Marc Stapley, I want to focus in on the three components of what happened in the quarter with Decipher. The guideline changes, the first category that you're talking about. I could see where the issues there, if we double-click on that, are maybe the market's more penetrated than you thought, and/or maybe visibility is a little bit lower in terms of what's going on and what had been driving growth. It's helpful to hear you highlight the three things, and I can tell by your face you don't agree with me, but that's fine, because that's the point of the question.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day